HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 05-02-2009, 08:45 AM   #1
Unregistered
Guest
 
Posts: n/a
AACR article

HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
Robert E. Roses 1, E. Carter Paulson 1, Anupama Sharma 1, Jeanne E. Schueller 1, Harvey Nisenbaum 2, Susan Weinstein 2, Kevin R. Fox 3, Paul J. Zhang 4, and Brian J. Czerniecki 1*
Departments of 1Surgery, 2Radiology, 3Medicine, and 4Pathology and Laboratory Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania



* To whom correspondence should be addressed. E-mail: brian.czerniecki@uphs.upenn.edu.


Abstract


The clinical implications of HER-2/neu (HER2) expression in ductal carcinoma in situ (DCIS) lesions have yet to be clearly elucidated; this despite the more frequent expression of HER2 in high-grade DCIS lesions compared with invasive cancers. We hypothesized that HER2 overexpression in DCIS is associated with more rapid progression to invasive disease. Immunohistochemical staining for estrogen receptor, progesterone receptor, and HER2 was done on DCIS specimens. Univariate analysis and a multivariate logistic regression were done to determine whether estrogen receptor, progesterone receptor, or HER2 status, comedo necrosis, nuclear grade, lesion size, or patient age predicted the presence of associated invasive disease in patients with DCIS. Invasive foci were found in association with HER2 overexpressing DCIS at a higher frequency than with DCIS that did not overexpress HER2. Although high nuclear grade, large lesion size, and HER2 overexpression were all associated with the presence of invasive disease on univariate analysis, HER2 was the only significant predictor for the presence of invasive disease after multivariate adjustment (odds ratio, 6.4; P = 0.01). These data indicate that HER2 overexpression in DCIS lesions predicts the presence of invasive foci in patients with DCIS and suggest that targeting of HER2 in an early disease setting may forestall or prevent disease progression. (Cancer Epidemiol Biomarkers Prev 2009;18(5):OF1–4)

Key Words: DCIS, HER-2/neu, phenotype, microinvasion, breast cancer
  Reply With Quote
Old 05-02-2009, 08:46 AM   #2
Unregistered
Guest
 
Posts: n/a
The post above was from me...Soccermom!
  Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 06:29 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter